Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

Author's Avatar
Jan 17, 2023

Study's primary efficacy endpoint was not achieved at 12 months post-treatment
Company has implemented a reduction in force
Company will seek strategic alternatives and will be delisted from Nasdaq